NMT1: A Protein Implicated in Cellular Metabolism and Disease

Target Name: NMT1

NCBI ID: G4836

NMT1

NMT1: A Protein Implicated in Cellular Metabolism and Disease

NMT1, or Myristoyl-CoA:Protein N-MyristoylTransferase 1, is a protein that plays a crucial role in cellular metabolism. It is an enzyme that transfers the N-myristoyl group from myristoyl-CoA to various proteins, which is essential for the synthesis of fatty acids, such as acyl-CoA esters, fatty acids, and ketones. The encoded NMT1 gene is located on chromosome 19q31 and has been implicated in various cellular processes, including fatty acid synthesis, cell signaling, and metabolism.

Mutations in the NMT1 gene have been linked to various human diseases, including primary biliary cholangitis (PBC), a chronic autoimmune disorder that affects the liver and bile ducts, as well as Primary biliary hyperplasia (PBH), a genetic disorder that affects the production and function of bile acids. In addition, altered NMT1 activity has also been implicated in various diseases, including obesity, type 2 diabetes, and neurodegenerative disorders.

The function of NMT1 is regulated by various factors, including diet, exercise, and environmental factors. In cell culture, NMT1 has been shown to be involved in the synthesis of fatty acids, including omega-3 and omega-6 fatty acids, which are essential for brain and eye development, as well as maintaining cellular membrane stability. Additionally, NMT1 has been shown to play a role in cell signaling, with altered NMT1 activity being associated with various cellular signaling pathways, including the TOR signaling pathway, the PI3K/Akt signaling pathway, and the NF-kappa-B signaling pathway.

In addition to its role in cell signaling and metabolism, NMT1 has also been shown to have potential as a drug target or biomarker. For example, altered NMT1 activity has been linked to various diseases, including PBC and PBH. In addition, studies have shown that inhibiting NMT1 activity has potential therapeutic benefits for these diseases. For example, a compound called T528 has been shown to inhibit NMT1 activity and improve symptoms of PBC in animal models. Similarly, a compound called IDH has been shown to inhibit NMT1 activity and improve symptoms of PBH in dogs.

Another approach to target NMT1 is to modulate its activity by changing its expression level. This can be done by using techniques such as RNA interference, CRISPR/Cas9, or genetic modification to reduce the amount of NMT1 produced in the cell. For example, researchers have used RNA interference to reduce the expression of NMT1 in human liver cells, which resulted in improved insulin sensitivity and reduced fibrosis. Similarly, CRISPR/Cas9 has been used to modify the expression of NMT1 in animal models, resulting in decreased activity in the liver.

Overall, NMT1 is a protein that plays a crucial role in cellular metabolism and signaling. Its activity is regulated by various factors, including diet, exercise, and environmental factors. In addition, altered NMT1 activity has been implicated in various diseases, including PBC and PBH. The potential of NMT1 as a drug target or biomarker makes it an attractive target for researchers to study and develop new treatments for these diseases.

Protein Name: N-myristoyltransferase 1

Functions: Adds a myristoyl group to the N-terminal glycine residue of certain cellular and viral proteins (PubMed:22865860, PubMed:25255805, PubMed:9353336, PubMed:9506952). Also able to mediate N-terminal lysine myristoylation of proteins: catalyzes myristoylation of ARF6 on both 'Gly-2' and 'Lys-3' (PubMed:32103017, PubMed:32111831). Lysine myristoylation is required to maintain ARF6 on membranes during the GTPase cycle (PubMed:32103017)

The "NMT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NMT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets